BioSpace News Archive

Virios Therapeutics, Inc. announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the SHARE™️ Series Monday Management Update for investors on Monday, September 18, 2023, at 11:00 am ET.

Pixelgen Technologies ® , a leader in spatial proteomics for single cells, announced today that it has appointed life sciences professional Henrik Everberg, Ph.D., as its first Chief Operating Officer.

Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed Jason K. Garland as Chief Financial Officer (“CFO”), effective September 25, 2023.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it has completed enrollment and dosing in Study MMED008, the Company’s Phase 2b study evaluating MM-120 (lysergide D-tartrate) for the treatment of GAD.

TRIANA Biomedicines, Inc. today announced the appointments of Dr. Vito Palombel as Chief Scientific Officer and Dr. Reza Mazhari as Chief Business Officer.

Baylor Genetics announced the availability of a new Neurodevelopmental Disorders Panel for children and other patients affected by a suspected or clinically diagnosed autism spectrum disorder, intellectual disability, and/or developmental delay.

Avalyn Pharma Inc. and collaborators made several presentations at the congress of the European Respiratory Society (ERS), demonstrating that treatment with AP01 (inhaled pirfenidone) preserved forced vital capacity in participants with different forms of pulmonary fibrosis in the ongoing AP01-005 open label extension study, which followed the successful Phase 1b ATLAS study in idiopathic pulmonary fibrosis (IPF) patients.

Bolt Biotherapeutics, Inc. announced today the issuance of the first and foundational patent covering BDC-3042. The U.S. Patent and Trademark Office (USPTO) issued U.S. Patent 11,753,474 titled “Anti-Dectin-2 Antibodies,” on September 12, 2023.

Dewpoint Therapeutics and Chemify today announced a partnership to develop a suite of digitally discovered and automatically synthesized novel molecules on Chemify’s programmable chemistry platform against condensate targets of interest in Dewpoint’s oncology and neurodegeneration pipeline.

Waters Corporation announced new bioprocess walk-up solutions designed to further simplify biologic sample prep and analysis.